The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
28-Nov-18
$113 million
Target:
CSR Limited
Acquiror:
Crescent Capital Partners
Advised CSR Ltd, a leading building products manufacturer in Australia and New Zealand, on the divestment of its architectural glass manufacturing and processing business, Viridian
12-Sep-18
$NA
Target:
Uniseal, Inc.
Acquiror:
LG Chem Ltd.
Advised LG Chem, a global diversified chemicals manufacturer based in South Korea, on the acquisition of Uniseal, a US-based supplier of sealants and adhesives to leading automotive manufacturers
10-Sep-18
$100 million
Target:
Montserrat Day Hospital Group
Acquiror:
Primary Health Care
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
21-Aug-18
$171 million
Target:
Nihon Nohyaku Co., Ltd.
Acquiror:
ADEKA Corporation
Advised ADEKA Corporation, a global chemical manufacturer, on the acquisition of 51% stake of Nihon Nohyaku via the combination of the Tender Offer and Capital Injection
09-Aug-18
$1.2 billion
Target:
Martabe gold and silver mine
Acquiror:
PT United Tractors Tbk
Advised EMR Capital, a specialist resources private equity manager, on the sale of the Martabe gold and silver mine to United Tractors
25-Jul-18
$145 million
Target:
Park Electrochemical (Electronics Business)
Acquiror:
AGC Inc.
Advised Park Electrochemical, a leading high-performance electronics materials manufacturer, on the sale of its Electronics Business to AGC Inc.
28-Jun-18
$146 million
Target:
35% of Sabine Oil & Gas’ interest in oil and gas properties in East Texas
Acquiror:
Osaka Gas
Advised Osaka Gas, a Japanese utility, on the acquisition of 35% of Sabine Oil & Gas’s interest in oil and gas properties located primarily in Harrison and Panola Counties, Texas
13-May-18
$81 million
Target:
GWA Group Limited’s Door and Access Controls Business
Acquiror:
Allegion plc
Advised Allegion plc, a leading global security products and solutions provider, on the acquisition of GWA Group Limited’s Door & Access Systems Business, a leading provider of door furniture and commercial locksmith services in Australia
26-Apr-18
$151 million
Target:
Three Australia and New Zealand security businesses
Acquiror:
Anixter International Inc.
Advised Anixter on its acquisitions of Central Security Distribution Pty Limited, Atlas Gentech (NZ) Limited and Inner Range Pty Limited
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
20-Nov-17
$412 million
Target:
Godfrey Hirst
Acquiror:
Mohawk Industries
Advised Godfrey Hirst, the leading manufacturer, distributor and marketer of carpet and hard flooring in Australia and New Zealand, on its sale to Mohawk Industries, the NYSE-listed global flooring company
05-Nov-17
$NA
Target:
Jaybro
Acquiror:
CHAMP Private Equity
Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity
24-Aug-17
$NA
Target:
Morris Corporation
Acquiror:
Sodexo SA
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
03-Apr-17
$205 million
Target:
Inenco Group Pty Ltd
Acquiror:
Genuine Parts Company
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
25-Apr-16
$3.4 billion
Target:
Divestment assets of Ball and Rexam
Acquiror:
Ardagh Group SA
Advised Ball Corporation on the acquisition of Rexam plc and provided a fairness opinion to the Board of Directors of Ball Corporation on the sale of select metal beverage can assets in Europe, Brazil and the United States to satisfy certain regulatory requirements in connection with its proposed acquisition of Rexam
18-Mar-16
$NA
Target:
Sewells Group
Acquiror:
MSX International
Advised WorldMark on the sale of Sewells Group to MSX International, a global provider of outsourced business solutions. Sewells, headquartered in Shanghai, is a leading provider of automotive dealership development services across Asia Pacific, Africa and the Middle East
08-Dec-15
$6+ billion
Target:
Air Warfare Destroyer Reform Strategy
Advised the Commonwealth Government of Australia as represented by the Department of Finance in relation to the Air Warfare Destroyer Reform Strategy
20-Aug-15
$1.0 billion
Target:
COOEC Fluor Heavy Industries Co., Ltd.
Acquiror:
Fluor Corporation
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
04-Jun-15
$1.5 billion
Target:
Moorebank Intermodal Terminal Project
Acquiror:
Qube / Aurizon
Advised the Australian Government on the public-private partnership with a consortium comprising Qube (ASX: QUB) and Aurizon (ASX:AZJ) to develop and operate a A$1.9 billion import /export and interstate intermodal terminal as well as associated warehousing and rail infrastructure in Moorebank, Sydney